Actively Recruiting
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-05-14
10
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective of this Phase I study is to establish the safety of adjuvant concurrent immunotherapy and radiation therapy for urothelial bladder cancer.
CONDITIONS
Official Title
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of pure or mixed variant urothelial carcinoma, including specific subtypes like squamous or glandular differentiation
- Radical cystectomy and pelvic lymph node dissection performed within the last 48 weeks
- Pathologic stage T3 or higher disease with no distant metastasis
- Currently receiving adjuvant checkpoint inhibitor therapy
- No clinical evidence of residual or recurrent cancer based on recent history, physical exam, and chest, abdominal, and pelvic imaging
- Eligible for external beam radiation therapy with no prior radiation to the study region
- No inflammatory bowel disease, active connective tissue disorders, or medical/social reasons preventing radiation
- Age 18 years or older
- ECOG performance status between 0 and 2
- Concurrent non-investigational medications allowed
- CT simulation scan shows no recurrent disease
- Ability to understand and sign informed consent
You will not qualify if you...
- Urinary diversion with an orthotopic neobladder
- History of inflammatory bowel disease
- Prior partial or complete small bowel obstruction before or after bladder surgery
- Previous radiation therapy to the pelvis overlapping with planned treatment fields
- Planned chemotherapy or investigational drugs during radiation therapy
- Subtotal surgical removal with visible residual disease
- Prior or concurrent second invasive cancer affecting study results
- Severe active medical conditions that interfere with safe study completion
- History of Grade 3 or higher gastrointestinal toxicity from surgery or nivolumab before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
P
Project Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here